Jack Klapper
Jack Klapper has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Abe Marcadis
1 shared publicationB Charlesworth
AstraZeneca, Alderley Park, Macclesfield, UK
1 shared publicationC Lucas
Hospital Salengro, Lille, France
1 shared publication- Daniel Rowe
Palm Beach Research Center, 1897 Palm Beach Lakes Boulevard, Suite 120, West Palm Beach, FL, 33409, USA
1 shared publication James Weintraub
Michigan Head Pain & Neurological Institute, 3120 Professional Drive, Ann Arbor, MI, 48104, USA
1 shared publication- Joel E. Bernstein1 shared publication
Latest Publications
- 7 March 2005
- Published by Taylor & Francis in Journal Of Neuropathic Pain & Symptom Palliation
- Vol. 1 (1) , 69-76
High-Strength Capsaicin Cream 0.25% in a Lidocaine-Containing Vehicle (Axsain™) Is a Safe and Effective Adjunctive Treatment for Painful Diabetic Neuropathy or Postherpetic Neuralgia
A multi-center study was conducted to assess the clinical effectiveness and safety of high-strength capsaicin cream 0.25% in a lidocaine-containing vehicle for treatment of painful diabetic neuropathy (PDN) and postherpetic neuralgia (PHN). Eighty-three (83) patients with PDN (n = 56) or PHN (n = 27) who were already taking oral antiepileptics or tricyclic antidepressants with incomplete pain relief were enrolled. Capsaicin cream 0.25% in a lidocaine-con-taining vehicle was applied to painful areas three times daily for 6 weeks. Pain intensity was evaluated at Weeks 1,3, and 6 using an Average Weekly Pain Score. At Week 6, improvement was also assessed with a Subject Global Evaluation (SGE), a Physician Global Evaluation (PGE), and a Functional Assessment Questionnaire. Following 1,3, and 6 weeks of treatment, pain was reduced by 21%, 40%, and 50%, respectively, in patients with PDN, and by 24%, 39%, and 51%, respectively, in patients with PHN. On the SGE, 90% of patients with PDN were rated as Im...
- 7 March 2005
- Published by Taylor & Francis in Journal Of Neuropathic Pain & Symptom Palliation
- Vol. 1 (1) , 69-76
High-Strength Capsaicin Cream 0.25% in a Lidocaine-Containing Vehicle (Axsain™) Is a Safe and Effective Adjunctive Treatment for Painful Diabetic Neuropathy or Postherpetic Neuralgia
A multi-center study was conducted to assess the clinical effectiveness and safety of high-strength capsaicin cream 0.25% in a lidocaine-containing vehicle for treatment of painful diabetic neuropathy (PDN) and postherpetic neuralgia (PHN). Eighty-three (83) patients with PDN (n = 56) or PHN (n = 27) who were already taking oral antiepileptics or tricyclic antidepressants with incomplete pain relief were enrolled. Capsaicin cream 0.25% in a lidocaine-con-taining vehicle was applied to painful areas three times daily for 6 weeks. Pain intensity was evaluated at Weeks 1,3, and 6 using an Average Weekly Pain Score. At Week 6, improvement was also assessed with a Subject Global Evaluation (SGE), a Physician Global Evaluation (PGE), and a Functional Assessment Questionnaire. Following 1,3, and 6 weeks of treatment, pain was reduced by 21%, 40%, and 50%, respectively, in patients with PDN, and by 24%, 39%, and 51%, respectively, in patients with PHN. On the SGE, 90% of patients with PDN were rated as Im...
- 1 November 2004
- Published by SAGE Publications in Cephalalgia
- Vol. 24 (11) , 918-924
Benefits of Treating Highly Disabled Migraine Patients with Zolmitriptan while Pain is Mild
Clinical trials of migraine therapy often require treatment when migraine pain intensity is moderate or severe, but many physicians find this practice artificial and patients often prefer to treat while pain is mild. This randomized, placebo-controlled study assessed the efficacy of zolmitriptan 2.5 mg in treating migraine while pain is mild, in patients who typically experience migraine attacks that are initially mild, but progress to moderate or severe. The intent-to-treat population comprised 280 patients (138 zolmitriptan; 148 placebo), with mean MIDAS grades of 29.6 (zolmitriptan) and 27.6 (placebo). Zolmitriptan 2.5 mg provided a significantly higher pain-free rate at 2 h (43.4% vs. 18.4% placebo; P <0.0001). Significantly fewer zolmitriptan patients reported progression of headache pain to moderate or severe intensity 2 h postdose (53.7% vs. 70.4% placebo; P < 0.01), or required further medication within 24 h (46.4% vs. 71.1% placebo; P <0.0001). The efficacy of zolmitriptan was more pronounced in patients treating during the first 15 min following pain onset. Adverse events were reported in 31.2% of patients treated with zolmitriptan (vs. 11.3% for placebo), and the incidence was lower in patients who treated early after attack onset. Zolmitriptan provides high efficacy when treating migraine while pain is mild, with the clinical benefits being more pronounced when treating early after migraine onset.
- 1 November 2004
- Published by SAGE Publications in Cephalalgia
- Vol. 24 (11) , 918-924
Benefits of Treating Highly Disabled Migraine Patients with Zolmitriptan while Pain is Mild
Clinical trials of migraine therapy often require treatment when migraine pain intensity is moderate or severe, but many physicians find this practice artificial and patients often prefer to treat while pain is mild. This randomized, placebo-controlled study assessed the efficacy of zolmitriptan 2.5 mg in treating migraine while pain is mild, in patients who typically experience migraine attacks that are initially mild, but progress to moderate or severe. The intent-to-treat population comprised 280 patients (138 zolmitriptan; 148 placebo), with mean MIDAS grades of 29.6 (zolmitriptan) and 27.6 (placebo). Zolmitriptan 2.5 mg provided a significantly higher pain-free rate at 2 h (43.4% vs. 18.4% placebo; P <0.0001). Significantly fewer zolmitriptan patients reported progression of headache pain to moderate or severe intensity 2 h postdose (53.7% vs. 70.4% placebo; P < 0.01), or required further medication within 24 h (46.4% vs. 71.1% placebo; P <0.0001). The efficacy of zolmitriptan was more pronounced in patients treating during the first 15 min following pain onset. Adverse events were reported in 31.2% of patients treated with zolmitriptan (vs. 11.3% for placebo), and the incidence was lower in patients who treated early after attack onset. Zolmitriptan provides high efficacy when treating migraine while pain is mild, with the clinical benefits being more pronounced when treating early after migraine onset.